Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Incyte Corporation
National Cancer Institute (NCI)
Children's Oncology Group
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Medical College of Wisconsin
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Radiation Therapy Oncology Group
Celgene
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Radiation Therapy Oncology Group
OHSU Knight Cancer Institute
TVAX Biomedical
St. Jude Children's Research Hospital
Children's Oncology Group
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University of South Florida
National Cancer Institute (NCI)
University of California, San Francisco
Radiation Therapy Oncology Group
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Northwestern University
Children's Oncology Group
Children's Oncology Group
Case Comprehensive Cancer Center
University of California, San Francisco
Northwestern University
Northwestern University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Alliance for Clinical Trials in Oncology
Children's Oncology Group
University of California, San Francisco
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dana-Farber Cancer Institute